Based on NCCN Clinical Practice Guidelines v3.2026 (November 24, 2025)
SECTION 1: INITIAL EVALUATION & WORKUP (EVAL-1)
Source: NCCN AML v3.2026 EVAL-1 / EVAL-2
1.1 Baseline Labs & Diagnostics[ZA1]
- CBC with differential, CMP, uric acid, LDH, B12/folate
- PT/PTT/fibrinogen (screen for DIC – critical in AML!)
- Bone marrow biopsy + aspirate: IHC, flow cytometry, cytogenetics (conventional karyotype), FISH, NGS multiplex panel
- Molecular testing: FLT3-ITD/TKD, NPM1, CEBPA (bZIP), IDH1/2, TP53, ASXL1, RUNX1, SRSF2, SF3B1, BCOR, EZH2, STAG2, U2AF1, ZRSR2, KIT, KRAS/NRAS, KMT2A rearrangements
- Echocardiogram or MUGA (history/symptoms of cardiac disease or planned cardiotoxic therapy)
- QTc interval – critical before quizartinib or revumenib
- G6PD level – required before rasburicase (rasburicase CI in G6PD deficiency)
- CNS evaluation: CT brain (rule out hemorrhage), MRI with/without contrast (if meningitis suspected), LP if symptomatic
- FDG-PET/CT if extramedullary disease suspected
- HLA typing (early referral to transplant center)
- CMV serology (potential HCT candidates)
- Fertility preservation counseling (young patients)
- Palliative care integration (early)
Immediate Pharmacist Actions at Diagnosis:
⚠️ PHARMACIST WATCHOUT: APL EMERGENCY: If clinical or pathologic features of APL → START ATRA [ZA2] [ZA3] IMMEDIATELY upon first suspicion. Do NOT wait for cytogenetics. Early ATRA prevents fatal DIC[ZA4] [ZA5] /hemorrhage.
⚠️ PHARMACIST WATCHOUT: HYPERLEUKOCYTOSIS [ZA6] (WBC >100 x 10⁹/L): Start hydroxyurea immediately. Consider cytarabine 0.5–2 g as bridge. Leukapheresis is controversial. WBC must be reduced to <25 x 10⁹/L before starting venetoclax (TLS risk).
⚠️ PHARMACIST WATCHOUT: TLS PROPHYLAXIS: Allopurinol or rasburicase + IV hydration. Check G6PD before rasburicase. Rasburicase preferred if: rapidly rising blasts, high uric acid, or renal impairment[ZA7] .
💎 CLINICAL PEARL: Rasburicase is contraindicated in G6PD deficiency (causes hemolytic anemia). Always check G6PD before administering. If urgency prevents lab check and G6PD deficiency is suspected, use allopurinol instead.
💎 CLINICAL PEARL: In APL: Do NOT give anthracycline alone without ATRA. Differentiation syndrome [ZA8] risk is managed with prophylactic prednisone [ZA9] (start with ATRA; switch to dexamethasone 10 mg IV Q12h if differentiation syndrome develops).
| Finding | Interpretation | Clinical Significance |
| WBC elevated | Leukocytosis due to circulating blasts | High WBC (>100 x 10⁹/L) = hyperleukocytosis → leukostasis risk |
| WBC low or normal | AML can present with leukopenia | Do not miss AML because WBC is normal |
| Blasts on differential | % blasts in PB; ≥20% blasts = AML diagnosis (per WHO) | Identifies AML; circulating blasts confirm bone marrow involvement |
| Anemia (low Hgb) | Marrow failure → decreased RBC production | Transfusion trigger (Hgb ≤7–8 g/dL per NCCN AML-F) |
| Thrombocytopenia | Marrow failure → decreased platelet production | Bleeding risk; transfusion trigger <10,000/mcL; APL = DIC risk |
| Neutropenia (low ANC) | Normal neutrophils replaced by blasts | Immunosuppression → infection risk; febrile neutropenia management |
| Creatinine/BUN elevated | Renal impairment | Cytarabine dose adjustment at ≥2 g/m²; venetoclax (no adjustment but monitor); etoposide (dose reduce if CrCl <50 mL/min). TLS causes acute kidney injury |
| AST/ALT/Bilirubin (LFTs) elevated | Hepatic involvement or drug toxicity | Dose adjust: idarubicin (bili >2.5 mg/dL → avoid), etoposide (bili >3 → avoid), daunorubicin (bili >3 → 50% dose), GO (avoid in hepatic VOD). Also baseline before hepatotoxic therapy |
| Potassium high | TLS (cell lysis releases K⁺) | Hypokalemia from TLS-driven treatment (alkalinization). QTc risk with hypokalemia + FLT3 inhibitors/ATO. Hyperkalemia → cardiac arrhythmia |
| Phosphorus high | TLS (cells release phosphate) | Hyperphosphatemia causes hypocalcemia → tetany, seizure |
| Calcium low | Hypocalcemia secondary to hyperphosphatemia | Cardiac arrhythmias, neuromuscular excitability |
| Sodium low | SIADH (rare) | Electrolyte baseline |
| Glucose low | Stress hyperglycemia; steroid-related Sepsis | Affects steroid antiemetic decision |
| Albumin high | Malnutrition, cancer wasting | Affects drug protein binding (relevant for phenytoin, etc.) |
| Alk Phos low | Liver/bone involvement, VOD | GO monitoring |
| Uric acid Elevated at diagnosis | High tumor burden, spontaneous cell turnover | Start allopurinol or rasburicase IMMEDIATELY. Elevated baseline uric acid = TLS risk classification as high |
| Uric acid Rapidly rising | Leukemic cells dying → TLS imminent | Rasburicase preferred (faster-acting, directly degrades uric acid to soluble allantoin) |
| Uric acid Normal | Baseline; does not rule out TLS after chemotherapy | Still start prophylaxis before treatment |
| LDH Very high (>2x ULN) | High leukemic burden; rapid cell turnover → HIGH TLS risk. Also associated with worse prognosis per NCCN Discussion (prognostic relevance) | |
| PT prolonged | Clotting factor depletionDIC consuming factors II, V, VII, X |
💎 CLINICAL PEARL: In APL specifically, thrombocytopenia + coagulopathy = potentially fatal DIC. The CBC directs the URGENCY of treatment (especially platelet transfusion trigger).
💎 CLINICAL PEARL: Uric Acid Role: Uric acid is the end product of purine metabolism. When leukemic blasts die rapidly (spontaneously or from chemotherapy), nucleic acids are released → broken down to hypoxanthine/xanthine → uric acid. Uric acid elevation crystallizes in renal tubules → obstructive nephropathy → acute kidney injury. This is a PREVENTABLE cause of renal failure.
💎 CLINICAL PEARL: LDH (Lactate Dehydrogenase) Role: LDH is an intracellular enzyme released when cells lyse. It is a direct marker of tumor burden and cellular turnover.
💎 CLINICAL PEARL: LDH + uric acid together define the spontaneous TLS risk BEFORE chemotherapy starts. Together with WBC and blast count, they guide whether you use allopurinol vs. rasburicase.
💎 CLINICAL PEARL: PT/PTT/Fibrinogen Role: Coagulation screen to detect DIC — which is LIFE-THREATENING in AML, and near-universal in APL.
💎 CLINICAL PEARL: jkn
SECTION 2: ELN 2022 RISK STRATIFICATION (AML-A)
Source: NCCN AML v3.2026 AML-A | ELN 2022 (Döhner H, et al. Blood 2022)
⚡ KEY CONCEPT: ELN 2022 risk stratification drives BOTH induction regimen selection AND post-remission strategy (alloHCT vs consolidation chemo). Every AML patient requires cytogenetics + NGS at diagnosis.
| Risk Category | Cytogenetic/Molecular Features | Post-Remission Implication |
| FAVORABLE | t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 inv(16)(p13.1q22) or t(16;16)/CBFB::MYH11 Mutated NPM1 (without FLT3-ITD) bZIP in-frame mutated CEBPA | HiDAC consolidation preferred over alloHCT in CR1 (unless MRD+). Add GO (CD33+) to induction (category 1 preferred). |
| INTERMEDIATE | Mutated NPM1 with FLT3-ITD Wild-type NPM1 with FLT3-ITD (no adverse lesions) t(9;11)(p21.3;q23.3)/MLLT3::KMT2A Cytogenetic/molecular NOS (not favorable or adverse) | AlloHCT in CR1 generally recommended. FLT3 inhibitor (midostaurin or quizartinib) added to induction and maintenance. |
| POOR/ ADVERSE | t(6;9)(p23.3;q34.1)/DEK::NUP214 t(v;11q23.3)/KMT2A-rearranged (non-MLLT3) t(9;22)/BCR::ABL1 t(8;16)(p11.2;p13.3)/KAT6A::CREBBP inv(3)/t(3;3)/GATA2, MECOM(EVI1) -5 or del(5q); -7; -17/abn(17p) Complex karyotype (≥3 abnormalities); monosomal karyotype Mutated: ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2 Mutated TP53 → strongly consider clinical trial | AlloHCT in CR1 (if achieved). CPX-351 preferred for secondary/therapy-related AML in age ≥60 y (category 1). TP53-mutant: NO preferred regimen; clinical trial strongly recommended. |
💎 CLINICAL PEARL: CEBPA: Only bZIP in-frame mutations confer favorable risk per ELN 2022. Single vs biallelic mutation distinction was removed[ZA10] . Verify the mutation type on the molecular report.
💎 CLINICAL PEARL: FLT3-ITD: Intermediate risk regardless of allelic ratio per ELN 2022. However, high allelic ratio (>0.5) historically associated with worse outcomes – some centers treat more aggressively.
💎 CLINICAL PEARL: TP53 mutation: Lowest benefit category for venetoclax-based regimens per AML-J. Clinical trial is the preferred recommendation. No standard regimen has demonstrated clear superiority.
💎 CLINICAL PEARL: KIT mutation: In CBF-AML (t(8;21) or inv(16)), KIT mutation is associated with worse prognosis but does NOT change risk category per ELN 2022 – monitor for emerging data.
💎 CLINICAL PEARL: Venetoclax Benefit by Mutation (AML-J): Higher benefit = TP53-wild, KRAS-wild, NRAS-wild, FLT3-ITD-negative. Intermediate = KRAS/NRAS mutated or FLT3-ITD+, TP53-wild. Lower benefit = TP53-mutant.
SECTION 3: TREATMENT DECISION ALGORITHM
Source: NCCN AML v3.2026 AML-1 through AML-9
3.1 Intensive Induction Eligible (Fit Patients)
Key eligibility criteria: ECOG PS 0–2, adequate organ function, no major contraindications to intensive chemotherapy. Age alone does not preclude intensive therapy.
Favorable/Intermediate Risk (AML-1):
- Preferred: 7+3 (daunorubicin or idarubicin) + gemtuzumab ozogamicin (CD33+)
- Other Recommended: 7+3 alone | FLAG-IDA ± gemtuzumab ozogamicin | CLAG-M
- FLT3 mutation: 7+3 + midostaurin (ITD or TKD) OR 7+3 + quizartinib (ITD only)
Poor/Adverse Risk – Without TP53 (AML-2):
- Age ≥60 y: CPX-351 preferred (category 1) | Age <60 y: 7+3 preferred
- Also recommended: Aza+Ven | Dec+Ven | CLIA+Ven | FLAG-IDA+Ven (use with caution >60 y)
Poor/Adverse Risk – TP53 Mutated (AML-2):
- CLINICAL TRIAL is the preferred recommendation
- Other recommended: 7+3 | CPX-351 (2B) | Flag-IDA (2B) | Aza+Ven | Dec+Ven | CLAG-M | CLIA+Ven
3.2 Intensive Induction Ineligible or Patient Declines (AML-4)
Lower-intensity therapy options – organized by FDA approval status and evidence level:
| Regimen | Dosing (NCCN AML-E) | Indication/Notes |
| Aza + Venetoclax | Aza 75 mg/m² SC/IV D1–7 of 28-day cycle; Ven PO 100→200→400 mg ramp-up D1-3 | Preferred. FDA approved. VIALE-A trial (OS benefit). Inpatient cycle 1 strongly recommended. |
| Dec + Venetoclax | Dec 20 mg/m² IV D1–5 (or D1–10); Ven PO 100→200→400 mg ramp-up D1–3 | Preferred. FDA approved (D1–5). VIALE-A/phase 1b data. |
| Aza + Ivosidenib (IDH1+) | Aza 75 mg/m² D1–7 or D1–5,8,9; Ivo 500 mg PO QD D1–28 | Category 1 preferred. FDA approved. AgIQ trial. Criteria: age >75, ECOG 2, severe cardiac/pulmonary, bilirubin >1.5 ULN, CrCl <45, or comorbidity. |
| Aza monotherapy | 75 mg/m² SC/IV D1–7 of 28-day cycle | Alternative if venetoclax contraindicated. |
| Dec monotherapy | 20 mg/m² IV D1–5 of 28-day cycle | Alternative if venetoclax contraindicated. |
| Ivosidenib (IDH1+) | 500 mg PO QD D1–28 | Monotherapy for IDH1-mutant AML. |
| Olutasidenib (IDH1+) | 150 mg PO BID D1–28 | IDH1-mutant AML. Monitor QTc. |
| Enasidenib (IDH2+) | 100 mg PO QD D1–28 | IDH2-mutant AML. Risk of differentiation syndrome. |
| Aza + Enasidenib (IDH2+) | Aza 75 mg/m² D1–7 + Enasidenib 100 mg PO QD D1–28 | IDH2-mutant AML. |
| Gilteritinib (FLT3+) | 120 mg PO QD D1–28 | FLT3-ITD or TKD mutation. |
| Gilteritinib + Aza (FLT3+) | 120 mg PO QD D1–28 + Aza 75 mg/m² D1–7 | FLT3-ITD or TKD mutation. |
| LDAC + Venetoclax | LDAC 20 mg/m²/day SC D1–10; Ven ramp-up 100→200→400→600 mg D1–4 | Preferred if HMA not feasible. |
| LDAC + Glasdegib | LDAC 20 mg SC Q12h D1–10 + Glasdegib 100 mg PO QD D1–28 | CLARITY trial. Alternative option. |
| Gemtuzumab Ozogamicin (CD33+) | 6 mg/m² D1 + 3 mg/m² D8 | Single-agent option in lower intensity setting. |
| Cladribine + LDAC + Ven | Clad 5 mg/m² D1–5 + LDAC 20 mg SC BID D1–10 + Ven D1–21 (induction); complex alternating consolidation schedule | Induction + multiple alternating consolidation courses. |
SECTION 4: DETAILED DOSING OF KEY REGIMENS (AML-E)
Source: NCCN AML-E 1–10 of 14 | v3.2026
4.1 Standard 7+3 Induction
| Drug | Dose | Route | Schedule | Key Notes |
| Cytarabine | 100 or 200 mg/m²/day | IV continuous infusion | Days 1–7 | 200 mg/m² preferred by many centers; both doses are guideline options. |
| Daunorubicin | 60 mg/m²/day* or 90 mg/m² (<60 y) | IV | Days 1–3 | *ECOG: 90 mg/m² superior in <60 y (OS benefit). For >65y: 60 mg/m² preferred (no benefit from 90 mg/m²). 60 mg/m² now preferred by some over 90 mg/m². |
| OR Idarubicin | 12 mg/m²/day | IV | Days 1–3 | Equivalent to daunorubicin 90 mg/m² for ages 60–65. Preferred at many centers. |
Reinduction (residual disease on D14 BM biopsy): Cytarabine CI x additional days + daunorubicin 45 mg/m² x 2 (if 90 mg/m² used in induction) or idarubicin 10 mg/m² x 1–2 doses.
4.2 7+3 + Gemtuzumab Ozogamicin (GO)
- GO 3 mg/m² (max one 4.5-mg vial) IV on Day 1, 2, 3, OR 4; OR Days 1, 4, and 7 (3 doses total)[ZA11]
- GCD33-positive tumors only – verify CD33 expression by flow cytometry or IHC
⚠️ PHARMACIST WATCHOUT: GO is a vesicant-like agent with risk of hepatic sinusoidal obstruction syndrome (SOS/VOD). Monitor LFTs closely. Premedicate per institutional protocol (acetaminophen + diphenhydramine). [ZA12] Infuse over 2 hours. If VOD develops → defibrotide[ZA13] .
💎 CLINICAL PEARL: GO single dose 3 mg/m² on ONE day vs. 3-dose schedule[ZA14] : NCCN allows both. Meta-analysis (Hills et al., Lancet Oncol 2014) showed OS benefit with GO in favorable/intermediate risk. Maximum benefit in favorable risk (CBF-AML).
4.3 7+3 + FLT3 Inhibitors[ZA15]
A. Midostaurin (FLT3-ITD or TKD) – RATIFY Trial
| Drug | Dose | Route | Schedule |
| Midostaurin | 50 mg PO Q12h | PO with food[ZA16] | Days 8–21 (during induction and consolidation cycles) |
| Continue as maintenance | 50 mg PO Q12h | PO | Days 1–28 x 12 cycles post-alloHCT/consolidation |
⚠️ PHARMACIST WATCHOUT: Midostaurin is a CYP3A4 substrate. Significant DDI with azole antifungals (posaconazole, voriconazole, fluconazole – CYP3A4 inhibitors) → increases midostaurin exposure[ZA17] . Balance infection risk vs. DDI; institutional protocols vary (often switch to micafungin).
💎 CLINICAL PEARL: RATIFY Trial (Stone et al., NEJM 2017): Midostaurin + 7+3 improved OS (HR 0.78) and EFS vs. placebo in FLT3+ newly diagnosed AML. Benefit seen regardless of FLT3-ITD allelic ratio or FLT3-TKD.
B. Quizartinib (FLT3-ITD ONLY) – QuANTUM-First Trial
| Drug | Dose | Route | Schedule | Key Notes |
| Quizartinib (induction) | 35.4 mg PO QD | PO | Days 8–21 | QTcF must be ≤450 ms before starting |
| Quizartinib (maintenance) | 26.5 mg → 53 mg PO QD | PO | D1–28 per cycle (up to 36 cycles) | Cycle 1 D1–14: 26.5 mg if QTcF ≤450. If QTcF ≤450 on D15 → escalate to 53 mg. Maintain 26.5 mg if QTcF ever >500 ms. |
⚠️ PHARMACIST WATCHOUT: QUIZARTINIB: QTc PROLONGATION [ZA18] IS A MAJOR CONCERN. QTcF >500 ms → hold/dose-reduce. Avoid concomitant QT-prolonging agents. Strong CYP3A4 inhibitors increase quizartinib levels. Electrolyte repletion (K+, Mg²+) is mandatory.
💎 CLINICAL PEARL: QuANTUM-First Trial (Erba et al., Lancet 2023): Quizartinib + 7+3 improved OS in newly diagnosed FLT3-ITD AML (HR 0.78). FLT3-ITD SPECIFIC – do NOT use for FLT3-TKD. Note: quizartinib is ITD-selective; midostaurin covers both ITD and TKD.
4.4 CPX-351 (Dual-Drug Liposomal Cytarabine + Daunorubicin)
| Drug | Dose | Route | Schedule | Notes |
| CPX-351 | Cytarabine 100 mg/m² + Daunorubicin 44 mg/m² | IV over 90 minutes | Days 1, 3, 5 (x 1 cycle induction) | Fixed 5:1 molar ratio (cytarabine:daunorubicin). Do NOT substitute with separate agents. |
- Preferred for: Age ≥60 y with therapy-related AML, AML with myelodysplasia-related changes (AML-MRC), antecedent MDS/CMML (category 1)
- Also appropriate for age <60 y with poor-risk features
⚠️ PHARMACIST WATCHOUT: CPX-351 is NOT the same as conventional 7+3. The liposomal formulation has different PK, longer half-life, and different toxicity profile. Do NOT dose-modify or substitute components. Monitor for extended myelosuppression (longer time to count recovery expected).
⚠️ PHARMACIST WATCHOUT: ANTHRACYCLINE CUMULATIVE DOSE: Convert CPX-351 daunorubicin dose to conventional units when calculating lifetime anthracycline exposure for cardiac risk assessment[ZA19] . Assess LVEF before treatment.
💎 CLINICAL PEARL: ADMIRAL Trial (Lancet 2020): CPX-351 vs. 7+3 in secondary AML (therapy-related or MDS/CMML-related). Improved median OS (9.56 vs. 5.95 months) and higher rate of alloHCT. Category 1 for age ≥60 y.
4.5 FLAG-IDA & FLAG-IDA + Venetoclax
| Drug | Dose | Route | Days | Notes |
| Fludarabine | 30 mg/m² | IV | Days 2–6 | In fludarabine shortage: substitute cladribine (CLAG-M). |
| Cytarabine (HiDAC) | 2 g/m² | IV over 4 hours | Days 2–6 (start 4h after fludarabine) | Use with CAUTION in ≥60 y or renal failure → cerebellar neurotoxicity risk. Steroid eye drops. |
| Idarubicin | 8 mg/m² | IV | Days 4–6 | Anthracycline component. |
| G-CSF (filgrastim)[ZA20] | SC | SC | Days 1–7 | G-CSF acts as a sensitizer, recruits leukemic cells into cycle (GCSF-priming strategy). |
| Venetoclax (if added) | 100 mg D1 → 200 mg D2 → 400 mg D3–7 | PO | Days 1–7 | Ramp-up required. Use with caution in >60 y. Venetoclax + FLAG-IDA: intensive regimen, significant cytopenias expected. |
⚠️ PHARMACIST WATCHOUT: HiDAC CYTARABINE NEUROTOXICITY: Cerebellar toxicity (nystagmus, ataxia, dysarthria, dysmetria) more common in age ≥60 y or renal impairment. MANDATORY neuro exam before EACH dose. If ANY cerebellar signs → STOP cytarabine immediately. Do NOT rechallenge.
⚠️ PHARMACIST WATCHOUT: STEROID EYE DROPS: All patients receiving cytarabine ≥2 g/m² MUST receive prophylactic steroid eye drops (e.g., prednisolone 1% 2 drops to each eye QID) starting Day 1 until 24–72 hours post-completion. Failure to prescribe → chemical conjunctivitis.
4.6 MEC Regimen – NCCN Template AML34 (Relapsed/Refractory)
NCCN Chemotherapy Order Template AML34 | NCCN AML v1.2026
| Drug | Dose | Route | Schedule (Option A, Days 1–5) | Schedule (Option B, Days 1–6) |
| MitoXANTRONE | 8 mg/m²/day (A) OR 6 mg/m²/day (B) | IV over 30 min | Days 1–5 | Days 1–6 |
| Etoposide | 100 mg/m²/day (A) OR 80 mg/m²/day (B) | IV over 60 min | Days 1–5 | Days 1–6 |
| Cytarabine (HiDAC) | 1,000 mg/m²/day | IV over 3 hours | Days 1–5 (given AFTER etoposide) | Days 1–6 (given AFTER etoposide) |
MEC Supportive Care (per NCCN AML34):
- Steroid eye drops: Prednisolone 1% 2 drops to EACH eye QID D1 of cytarabine, until 24–72 hours post-completion
- Moderate emetic risk:Antiemetics: Days 1–5 (Option A) or Days 1–6 (Option B): Dexamethasone dose may be modified or omitted (controversial in AML due to immunosuppression)
- TLS prophylaxis: Hydration + allopurinol (or rasburicase if high risk). Monitor electrolytes daily until TLS risk passes
- Mucositis monitoring: MEC-associated mucositis risk. Oral care protocols, topical mouthwashes, opioids, IV hydration as needed
- Central venous access device (CVAD) recommended for this regimen
MEC Monitoring (per NCCN AML34):
- CBC with differential: as clinically indicated
- Electrolytes, uric acid, renal function: at least DAILY (until TLS risk resolved)
- LFTs: prior to each cycle and as clinically indicated (for MitoXANTRONE and etoposide dose adjustments)
- Neurological exam: before each cytarabine dose (cerebellar toxicity monitoring)
- Renal function: prior to each cycle (etoposide and cytarabine dose modification)
- LVEF: prior to initiation (mitoXANTRONE is anthracycline-like – monitor cumulative anthracycline dose)
MEC Pharmacist Safety Watchouts (NCCN AML34):
⚠️ PHARMACIST WATCHOUT: MitoXANTRONE is a VESICANT – verify CVAD placement and patency before administration. Extravasation can cause severe tissue damage.
⚠️ PHARMACIST WATCHOUT: MitoXANTRONE cumulative cardiotoxicity: monitor total lifetime anthracycline equivalents. LVEF assessment required before initiation. Secondary malignancies associated with mitoXANTRONE (package insert review required).
⚠️ PHARMACIST WATCHOUT: Etoposide is an IRRITANT. Must be administered through NON-PVC tubing (plasticizer leaching). Monitor for hypersensitivity/infusion reactions: anaphylaxis, hives, throat tightness, hypotension. Secondary malignancies (therapy-related AML/MDS) associated with etoposide.
⚠️ PHARMACIST WATCHOUT: Etoposide hypersensitivity: reduce infusion rate (over 60 min minimum), have epinephrine/diphenhydramine/steroids available. If reaction occurs → slow/stop infusion, premedicate, consider rechallenge per institutional protocol.
⚠️ PHARMACIST WATCHOUT: LFT monitoring for etoposide: hepatic impairment → dose reduction required. Check total bilirubin, AST/ALT before each cycle.
💎 CLINICAL PEARL: MEC emetic risk is MODERATE (5- or 6-day regimen). Dexamethasone as antiemetic is controversial in AML due to immunosuppression. Consult NCCN Antiemesis guidelines. Consider 5-HT3 antagonists (ondansetron, granusetron) ± NK1 antagonist without steroids.
SECTION 5: CONSOLIDATION & MAINTENANCE THERAPY
Source: NCCN AML v3.2026 AML-6, AML-7, AML-E 6–7 of 14
5.1 Consolidation – Intensive Induction Eligible (AML-6)
| Risk Category | Preferred Consolidation | Notes |
| Favorable (CBF-AML, NPM1+, CEBPA bZIP) | HiDAC 3 g/m² IV over 3h Q12h Days 1,3,5 x 3–4 cycles | AlloHCT not required in CR1 for MRD-negative favorable risk. 3 g/m² ≥60 y: use 1–1.5 g/m² to reduce neurotoxicity. |
| Intermediate Risk (FLT3-ITD, others) | AlloHCT in CR1 preferred. Pre-HCT: HiDAC 1–3 g/m² | FLT3 inhibitor maintenance post-HCT (gilteritinib preferred if FLT3-MRD+). |
| Poor/Adverse Risk | AlloHCT in CR1 strongly preferred | CPX-351: If consolidation chemo needed, 1 cycle CPX-351 can be used (65 mg/m² day 1, 3). FLAG-IDA data also available. |
| Secondary/Therapy-related AML | AlloHCT preferred | or CPX-351 consolidation | CPX-351 consolidation: 65 mg/m² (cytarabine equivalent) Days 1, 3 IV over 90 min. |
⚠️ PHARMACIST WATCHOUT: HiDAC 3 g/m² Q12h in patients ≥60 years or CrCl <60 mL/min → HIGH neurotoxicity risk (cerebellar ataxia, confusion). Reduce to 1–1.5 g/m² per NCCN guideline footnote. Mandatory neuro exam prior each dose.
💎 CLINICAL PEARL: There is no evidence that cytarabine doses ≥2 g/m² are superior to 1–2 g/m² in intermediate-risk AML per NCCN footnote (AML-E 6A). For adverse risk, HiDAC is bridge to alloHCT, not definitive therapy.
5.2 Maintenance Therapy (AML-7)
| Drug | Dose/Schedule | Indication | Duration | Key Notes |
| Oral Azacitidine (CC-486) | 300 mg PO QD Days 1–14 of 28-day cycle | CR/CRi post-chemotherapy (no alloHCT) | Continue until relapse/toxicity | QUAZAR AML-001 trial (Wei et al., NEJM 2020): OS benefit (24.7 vs. 14.8 months). Approved for AML in CR/CRi post-intensive therapy, age ≥55 y, not eligible for HCT. |
| Gilteritinib (FLT3-ITD/TKD) | 120 mg PO QD Days 1–28 | Post-alloHCT or post-consolidation, FLT3+ AML | Up to 26 cycles | ADMIRAL trial maintenance data + FLT3-MRD-guided use. New NCCN: recommended post-HCT if FLT3-ITD MRD ≥10⁻⁶ by NGS (sensitivity ≤10⁻⁵). |
| Quizartinib (FLT3-ITD only) | 26.5 mg → 53 mg PO QD D1–28 | Post-consolidation, FLT3-ITD only | Up to 36 cycles | QTcF monitoring mandatory. Cycle 1 D1–14: 26.5 mg; escalate to 53 mg if QTcF ≤450 ms on D15. |
| Midostaurin (FLT3-ITD/TKD) | 50 mg PO BID D1–28 | Post-consolidation, FLT3+ AML | 12 cycles | RATIFY protocol. DDI with azoles (see above). |
| Sorafenib (FLT3-ITD only) | 200 mg BID x3 cycles → 400 mg BID | Post-alloHCT, FLT3-ITD | Up to 24 months | Off-label; limited by toxicity (hypertension, hand-foot syndrome, diarrhea). |
| Azacitidine SC | 50 mg/m² SC D1–5 of 28-day cycle | Post-remission (non-HCT eligible) | Max 12 cycles | Alternative to oral azacitidine. |
| Decitabine | 20 mg/m² IV D1–5 of 28–56-day cycle; or D1–3 of 28-day cycle | Post-remission maintenance | Max 12 cycles | Alternative option; less evidence than oral aza. |
| Low-dose decitabine | 5 mg/m² IV D2–6 + G-CSF SC D1–6 | Maintenance option | Variable | NCCN listed; institutional use. |
💎 CLINICAL PEARL: QUAZAR AML-001: Oral azacitidine 300 mg (NOT same as injectable 75 mg/m²). Oral formulation has different bioavailability. Do NOT substitute injectable formulation for oral. Brand name: Onureg.
💎 CLINICAL PEARL: G-CSF must be stopped ≥7 days before BM biopsy to assess remission status (to avoid confounding neutrophil recovery with persistent disease).
SECTION 6: VENETOCLAX PRINCIPLES (AML-J)
Source: NCCN AML v3.2026 AML-J 1–4 of 4 | VIALE-A Trial (DiNardo et al., NEJM 2020)
6.1 Venetoclax Ramp-Up Dosing
| Day | Ven + HMA (Aza or Dec) | Ven + LDAC | Purpose |
| Day 1 | 100 mg PO once daily | 100 mg PO once daily | Ramp-up to minimize TLS risk |
| Day 2 | 200 mg PO once daily | 200 mg PO once daily | |
| Day 3 | 400 mg PO once daily | 400 mg PO once daily | |
| Day 4+ | 400 mg PO once daily | 600 mg PO once daily | LDAC uses higher target dose (600 mg) |
6.2 TLS Risk & Monitoring (Cycle 1)
- Reduce WBC to <25 x 10⁹/L with hydroxyurea/leukapheresis BEFORE starting venetoclax
- INPATIENT treatment strongly recommended for Cycle 1 (especially through ramp-up)
- Allopurinol or other uric acid–lowering agent until no further TLS risk
- Monitor blood chemistries (electrolytes, uric acid, creatinine, phosphorus, LDH) every 6–8 hours x 24 hours after maximum dose escalation; then daily until TLS risk resolved
- Aggressively manage electrolyte imbalances (K+, phosphorus, Ca²+, uric acid)
6.3 Cycle Management & Dose Modifications (AML-J 3 of 4)
| Situation | Action |
| BM day 21–28 shows CR | Delay cycle 2 up to 14 days for ANC >0.5 x 10⁹/L and platelets >50 x 10⁹/L. G-CSF encouraged. Consider reducing venetoclax duration to 21 days. |
| BM day 21–28 shows MLFS or CRi | Start cycle 2 without delay. Continue monitoring. |
| Cycle 3+: cytopenias recur | Delay next cycle up to 14 days for ANC/plt recovery. G-CSF encouraged. Reduce venetoclax duration: 14 days → 7 days → 5 days as needed. |
| Substantial comorbidities (new) | Consider initiating venetoclax at reduced duration (e.g., 7 days) per AML-J 2 of 4. |
| Lack of response after ≤4 cycles | Consider switch to R/R therapy (AML-9). Response most commonly seen after 2 cycles; reasonable to stop after 2 cycles if no response. |
| Concurrent strong CYP3A4 inhibitor (e.g., posaconazole, voriconazole, ketoconazole) | Reduce venetoclax to 70 mg (if on 400 mg) or reduce accordingly per package insert. Consult pharmacist. |
| Concurrent moderate CYP3A4 inhibitor (e.g., fluconazole, diltiazem, erythromycin) | Reduce venetoclax by ~50%. Consult package insert and pharmacist. |
| Strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin) | AVOID – significantly reduces venetoclax efficacy. |
| P-gp inhibitors (e.g., amiodarone, clarithromycin) | Use with caution; may increase venetoclax levels. |
⚠️ PHARMACIST WATCHOUT: VENETOCLAX DDI – HIGH PRIORITY: Azole antifungals (posaconazole = strong CYP3A4 inhibitor; fluconazole = moderate) INCREASE venetoclax levels significantly. DOSE ADJUSTMENT IS MANDATORY. Document dose reduction in the chart. Failure to adjust → severe myelosuppression and potentially fatal TLS.
⚠️ PHARMACIST WATCHOUT: TUMOR LYSIS SYNDROME (TLS): Venetoclax-based regimens in AML carry HIGH TLS risk in cycle 1. This is different from venetoclax in CLL (which uses a 5-week ramp-up as outpatient). In AML, inpatient monitoring during ramp-up is strongly recommended per NCCN.
💎 CLINICAL PEARL: VIALE-A Trial (DiNardo et al., NEJM 2020): Aza + Venetoclax improved OS (14.7 vs. 9.6 months) and CR rate (36.7% vs. 17.9%) vs. azacitidine alone in treatment-naive, intensive therapy-ineligible AML. Subgroup analysis: highest benefit in NPM1-mutant, IDH1/2-mutant AML. Lowest benefit in TP53-mutant AML.
💎 CLINICAL PEARL: PROGNOSTIC STRATIFICATION for HMA+Ven benefit (AML-J 1 of 4 – NEW in v3.2026): Higher benefit = negative for TP53, KRAS, NRAS, FLT3-ITD. Intermediate = KRAS/NRAS or FLT3-ITD+, TP53-wild. Lower benefit = TP53-mutant. This guides counseling and alternative considerations.
SECTION 7: RELAPSED / REFRACTORY AML (AML-8, AML-9)
Source: NCCN AML v3.2026 AML-9, AML-E 8–10 of 14
7.1 Targeted Therapies in R/R AML
| Drug | Target | Dose | Key Pharmacist Note |
| Gilteritinib (Xospata) | FLT3-ITD or TKD | 120 mg PO QD D1–28 (28-day cycle) | ADMIRAL trial: improved OS vs. salvage chemo in R/R FLT3+ AML. QTc monitoring. CYP3A4 substrate. Risk of differentiation syndrome (similar to IDH inhibitors). Avoid strong CYP3A4 inducers. |
| Quizartinib (Vanflyta) | FLT3-ITD only | 26.5→53 mg PO QD (QTcF-guided) | QTc prolongation: dose at 26.5 mg D1–14; escalate to 53 mg if QTcF ≤450 ms D15. Maintain 26.5 mg if QTcF ever >500 ms. Strong DDI with CYP3A4 inhibitors. |
| Enasidenib (Idhifa) | IDH2 mutation | 100 mg PO QD D1–28 | IDH-INHIBITOR DIFFERENTIATION SYNDROME RISK (fever, SOB, pulmonary infiltrates, lymphadenopathy, edema). Treat with dexa 10 mg IV Q12h. Do NOT stop enasidenib unless severe. Leukocytosis may occur. |
| Ivosidenib (Tibsovo) | IDH1 mutation | 500 mg PO QD D1–28 | Same differentiation syndrome risk as enasidenib. Also QTc prolongation risk. Strong CYP3A4 inhibitors increase levels. Food reduces absorption – take on empty stomach or consistent with meals. |
| Olutasidenib (Rezlidhia) | IDH1 mutation | 150 mg PO BID D1–28 | IDH1-specific. QTc monitoring required. Take with or without food. Approval based on AUGMENT-101 trial. |
| Revumenib (Revuforj) | KMT2A rearrangement or NPM1 mutation | 160 mg PO BID (with strong CYP3A4 inh) OR 270 mg PO BID (without strong CYP3A4 inhibitor) | DOSE IS DIFFERENT based on co-administration of strong CYP3A4 inhibitor! Weight-based dosing for <40 kg patients. Differentiation syndrome risk. QTc prolongation. FDA approved 2023 for R/R AML. |
| Ziftomenib (Zilbrysq) new | NPM1 mutation | 600 mg PO QD D1–28 | NPM1-mutant AML (R/R). FDA approved 2025. Differentiation syndrome risk. New drug – monitor for updates on DDI profile. |
| Gemtuzumab Ozogamicin (GO – Mylotarg) | CD33-positive | 3 mg/m² (≤4.5 mg vial) D1, 4, 7 (R/R setting) | VOD/SOS risk – monitor LFTs, weight gain, RUQ pain. CD33 must be verified. Infuse over 2 hours. Premedicate. |
| Azacitidine or Dec + Sorafenib (FLT3-ITD) | FLT3-ITD (off-label combination) | Aza 75 mg/m² D1–7 or Dec 20 mg/m² D1–10 + Sorafenib 400 mg PO BID | NCCN listed. Sorafenib toxicities: hypertension, hand-foot syndrome, diarrhea, hepatotoxicity. QTc monitoring. CYP3A4 substrate/inhibitor. |
7.2 Intensive Salvage Regimens in R/R AML (AML-E 9 of 14)
| Regimen | Dosing | Key Notes |
| MEC (NCCN AML34) | MitoXANTRONE 8 mg/m² (or 6 mg/m²) + Etoposide 100 mg/m² (or 80 mg/m²) + Cytarabine 1,000 mg/m² D1–5 (or D1–6) | Moderate emetic risk. CVAD required. |
| CLAG ± Mitoxantrone/ Idarubicin | Cladribine 5 mg/m² D2–6 + Cytarabine 2 g/m² D2–6 (2h after cladribine) + G-CSF D1–6 ± Mitoxantrone 10 mg/m² or Idarubicin 8 mg/m² D2–4 | Use with caution ≥60 y. Cytarabine ≥2 g/m² neurotoxicity risk. |
| FLAG ± Idarubicin | Fludarabine 30 mg/m² D2–6 + Cytarabine 2 g/m² D2–6 (4h after fludarabine) + G-CSF D1–5 ± Idarubicin 10 mg/m² D1–3 | Cladribine substitutable for fludarabine. |
| HiDAC ± Daunorubicin or Idarubicin | Cytarabine 2–3 g/m² Q12h D1–6 ± Daunorubicin 50 mg/m² or Idarubicin 12 mg/m² x3 days | HiDAC. Strict neuro monitoring. Steroid eye drops mandatory. |
| HiDAC ± Mitoxantrone | Cytarabine 1.5–3 g/m² Q12h D1–6 ± Mitoxantrone 10 mg/m² D7–9 |
💎 CLINICAL PEARL: REVUMENIB: Dose depends on whether the patient is receiving a strong CYP3A4 inhibitor (azole antifungals). If on posaconazole/voriconazole → 160 mg BID. If NOT → 270 mg BID. This is a critical counseling point. Differentiation syndrome risk is significant.
💎 CLINICAL PEARL: DIFFERENTIATION SYNDROME with IDH inhibitors (ivosidenib, enasidenib, olutasidenib) and FLT3 inhibitors (gilteritinib): Can mimic sepsis. Features: fever, pulmonary infiltrates, hypoxia, weight gain, edema, pleuritis. Treatment: dexamethasone 10 mg IV Q12h until resolution. Do NOT stop the inhibitor unless grade 3–4 despite steroids.
⚠️ PHARMACIST WATCHOUT: QTc MONITORING CHECKLIST for R/R AML: Quizartinib → mandatory QTcF. Ivosidenib → QTc prolongation. Olutasidenib → QTc monitoring. Sorafenib → QTc. Revumenib → QTc. Obtain baseline ECG and replete K+/Mg²+ before any of these agents.
SECTION 8: ACUTE PROMYELOCYTIC LEUKEMIA (APL)
Source: NCCN AML v3.2026 APL-1 through APL-6 | APL-A, APL-B
8.1 Risk Stratification & Treatment Selection
| Risk | Definition | Induction Regimen |
| Low Risk | WBC ≤10 x 10⁹/L, No cardiac issues | ATRA + Arsenic Trioxide (ATO) – Category 1 (Preferred) OR ATRA + Idarubicin (if ATO unavailable/contraindicated) |
| High Risk | WBC >10 x 10⁹/L | ATRA + Idarubicin + ATO or cytarabine (per protocol) (See APL-3 for full protocol details) |
| Cardiac Issues (Low EF or QTcF prolongation) | Any WBC + cardiac issues | Alternative induction: see APL-4 (modified regimen) |
8.2 APL Induction – Low Risk (ATRA + ATO, Category 1)
| Drug | Dose | Schedule | Phase |
| ATRA (tretinoin) | 45 mg/m²/day PO divided BID | Until clinical remission (typically ~28 days) | Induction + Consolidation |
| Arsenic Trioxide (ATO) | 0.15 mg/kg IV QD | Days 1–28 (induction); intermittent schedule (consolidation) | Induction + Consolidation |
| Idarubicin (if ATO unavailable) | 12 mg/m²/day | Days 2, 4, 6, 8 (every other day) | Alternative induction |
| Gemtuzumab Ozogamicin | Per APL-2 protocol | Alternative if arsenic contraindicated | Useful in certain circumstances |
Key APL Management Points:
- Start ATRA at FIRST SUSPICION – do not wait for confirmatory cytogenetics/FISH/PCR
- Begin steroid prophylaxis (prednisone) at ATRA initiation – differentiation syndrome prevention
- BM assessment Day 28–35 to document <5% blasts and no abnormal promyelocytes before consolidation
- Presence of molecular markers (PML::RARA) post-induction does NOT have prognostic implications (unlike AML)
- FLT3 inhibitors are NOT recommended for FLT3-positive APL (per NCCN footnote)
- For high cumulative anthracycline doses: reassess cardiac function before each anthracycline/mitoxantrone-containing course
⚠️ PHARMACIST WATCHOUT: APL DIFFERENTIATION SYNDROME: Occurs with ATRA and/or ATO. Features: fever ≥38°C, dyspnea, weight gain ≥5 kg, pulmonary infiltrates, pleural/pericardial effusion, hypotension. Treat with dexamethasone 10 mg IV Q12h at FIRST SIGN. Generally do NOT discontinue ATRA/ATO for mild-moderate syndrome.
⚠️ PHARMACIST WATCHOUT: ATO (Arsenic Trioxide) QTc PROLONGATION: Obtain baseline ECG. QTcF >500 ms → HOLD ATO and correct electrolytes. Monitor K+, Mg²+, Ca²+ daily during ATO treatment. Avoid concomitant QT-prolonging drugs.
⚠️ PHARMACIST WATCHOUT: APL COAGULOPATHY: APL is associated with FATAL HEMORRHAGE secondary to DIC + hyperfibrinolysis. Monitor PT/PTT/fibrinogen/D-dimer DAILY. Platelet target >50,000/mcL. Fibrinogen target >150 mg/dL. Cryoprecipitate and FFP as needed.
💎 CLINICAL PEARL: Lo-Coco et al. (NEJM 2013) and Platzbecker et al. (JCO 2017): ATRA+ATO is non-inferior to ATRA+chemotherapy in low-risk APL with BETTER tolerability and OS. Chemotherapy-free approach for low-risk APL is now the global standard.
SECTION 9: SUPPORTIVE CARE (AML-F)
Source: NCCN AML v3.2026 AML-F, AML-G
| Supportive Care Element | NCCN Recommendation | Pharmacist Watchout |
| Transfusion – RBC | Threshold: Hgb ≤7–8 g/dL (or per symptoms) | Use leukocyte-depleted products. CMV-seronegative products for HCT candidates. Irradiated for potential HCT or alloimmunized. |
| Transfusion – Platelets | Threshold: Plt <10,000/mcL OR any bleeding signs | Alloimmunized patients: HLA-matched or cross-match-compatible products. |
| TLS Prophylaxis | Hydration + Allopurinol (or rasburicase for high-risk) | G6PD check before rasburicase. Rasburicase CI: G6PD deficiency, pregnancy. Rasburicase contraindicated with allopurinol (use one or the other). |
| Central Venous Access (CVAD) | Recommended (multi-lumen) for all intensive therapy | Assess for line infection. Thrombosis monitoring. Remove/replace per clinical circumstances. |
| HiDAC Eye Prophylaxis | Prednisolone 1% drops BID to EACH eye starting D1 through 24–72h post-cytarabine completion | Must be ordered with EACH high-dose cytarabine course. Chemical conjunctivitis is preventable. Applies to ≥2 g/m² doses. |
| Cytarabine Neurotoxicity | Neuro exam (nystagmus, ataxia, dysarthria, dysmetria) before EACH HiDAC dose | STOP cytarabine permanently if cerebellar toxicity. No rechallenge with ≥2 g/m². Elevated creatinine during TLS → HOLD cytarabine ≥2 g/m² until creatinine normalizes. |
| Antifungal Prophylaxis | Posaconazole shown to significantly decrease fungal infections vs. fluconazole/itraconazole | Posaconazole = strong CYP3A4 inhibitor → adjust venetoclax, midostaurin, quizartinib, ivosidenib doses. Voriconazole, echinocandins, or AmBisome are alternatives. |
| Antibacterial Prophylaxis | Per institutional protocol and prevailing resistance patterns | Fluoroquinolone prophylaxis (levofloxacin) widely used but consider resistance. Review for DDI with QTc-prolonging agents. |
| Antiviral Prophylaxis | Acyclovir/valacyclovir (per institutional protocol, especially post-HCT) | Acyclovir dose adjustment in renal impairment. |
| PCP Prophylaxis | Consider during fludarabine-containing regimens and post-HCT | TMP-SMX preferred. If sulfa allergy: atovaquone or dapsone (check G6PD for dapsone). |
| G-CSF / Growth Factors | May be used in post-remission therapy support. Stop G-CSF ≥7 days before BM biopsy. | Do not administer G-CSF if active AML (stimulates leukemic proliferation). Exception: FLAG-IDA (intentional priming strategy). |
| DIC Management (APL) | Monitor fibrinogen, PT/PTT, D-dimer daily. Target fibrinogen >150 mg/dL, plt >50,000/mcL | Cryoprecipitate for fibrinogen replacement (10 units typically increases fibrinogen by ~50 mg/dL). FFP for PT correction. |
SECTION 10: MONITORING DURING INTENSIVE THERAPY (AML-G)
Source: NCCN AML v3.2026 AML-G | Monitoring During Intensive Therapy
10.1 Induction Monitoring
| Lab/Parameter | Frequency | Purpose/Action |
| CBC with differential | DAILY (differential daily during chemo; every other day after ANC >0.5 x 10⁹/L recovery) | Count recovery monitoring; detect neutrophil/platelet nadir; transfusion triggers. |
| Chemistry: electrolytes, LFTs, BUN/Cr, uric acid, phosphorus | At least DAILY during active treatment until TLS risk resolved | TLS monitoring; hepatotoxicity; renal function for dose adjustments. |
| Coagulation (PT/PTT/fibrinogen) | 1–2x/week (daily if DIC present) | DIC surveillance, especially APL. Daily if DIC confirmed. |
| Bone Marrow Biopsy Day 14–21 | Single assessment at D14–21 after induction start | Document hypoplasia (expected). If NOT hypoplastic → suspect persistent disease → repeat BM within 7 days. |
| BM Biopsy at Count Recovery | At time of hematologic recovery | Document remission. If initially abnormal cytogenetics → repeat cytogenetics. Consider MRD testing. |
| Nephrotoxic agent monitoring | More frequent during use (daily) | Dose adjustments for cytarabine, antimicrobials (vancomycin levels, etc.). |
| LVEF (ECHO/MUGA) | Before anthracycline-containing therapy and as clinically indicated | Cumulative cardiotoxicity monitoring. Repeat before each anthracycline/mitoxantrone course if high cumulative doses. |
| Neurological exam | Before EACH HiDAC dose (≥2 g/m²) | Cerebellar toxicity: nystagmus, ataxia, dysarthria, dysmetria. STOP cytarabine if present. |
| QTc (ECG) | Baseline + with QT-prolonging agents (quizartinib, ivosidenib, olutasidenib, ATO, sorafenib, revumenib) | QTcF >500 ms → hold/dose-reduce. Replete K+/Mg²+. |
| G6PD | Before rasburicase | CI if G6PD-deficient → use allopurinol. |
10.2 Measurable Residual Disease (MRD) Assessment (AML-H)
- MRD assessment is now integral to AML management – guides post-remission strategy
- Methods: Multiparameter flow cytometry (MFC), qPCR (for NPM1, CBF-AML, PML::RARA), NGS-targeted deep sequencing
- NGS-based MRD for FLT3-ITD: sensitivity ≤10⁻⁵ preferred (per NCCN v3.2026 update)
- BM FLT3-ITD MRD ≥10⁻⁶ by highly sensitive NGS pre- or post-alloHCT → post-transplant gilteritinib maintenance recommended (new NCCN update v3.2026)
- MRD positivity in favorable-risk AML → consider alloHCT (changes management from consolidation to transplant)
- As there is no clear optimal management of MRD positivity → clinical trial preferred if available
- Venetoclax-based low-intensity therapy has demonstrated high rates of MRD reduction in MRD+ and oligoblastic AML
💎 CLINICAL PEARL: MRD testing method MATTERS: Flow cytometry (sensitivity ~10⁻³–10⁻⁴), qPCR (10⁻⁴–10⁻⁶), NGS (10⁻⁵–10⁻⁷). NPM1-mutant AML: qPCR in peripheral blood is highly sensitive and specific. CBF-AML: qPCR for KIT2A::RUNX1T1 or CBFB::MYH11. FLT3-ITD: NGS preferred over standard PCR.
SECTION 11: DOSE ADJUSTMENTS – ORGAN DYSFUNCTION
| Drug | Renal Impairment | Hepatic Impairment | Other Adjustments |
| Cytarabine (≥2 g/m²) | CAUTION if CrCl <60 or rapidly rising Cr (TLS) → reduce to 1–1.5 g/m² or hold. Use 1–1.5 g/m² in age ≥60 y. | Minor hepatic metabolism; generally tolerated. | Age ≥60 y: reduce HiDAC dose to ≤1.5 g/m² to minimize neurotoxicity risk. |
| Daunorubicin | No specific dose reduction required (minimal renal excretion). | Bili 1.2–3 mg/dL: 75% dose. Bili >3 mg/dL: 50% dose. | Cumulative lifetime dose limit: ~550 mg/m² (reduced with prior RT). |
| Idarubicin | CrCl <10 mL/min: consider dose reduction. | Bili >2.5 mg/dL: do not administer. Bili 2–2.5 mg/dL: 50% dose. | Cumulative dose limit: ~150 mg/m². |
| Etoposide | CrCl 15–50 mL/min: 75% dose. CrCl <15 mL/min: consider 50%. | Bili 1.5–3: 50% dose. Bili >3: avoid. | Non-PVC tubing required. |
| MitoXANTRONE | Not renally eliminated; no adjustment generally needed. | Bili >3.4 mg/dL: consider dose reduction (not fully established). | Cumulative dose: monitor for cardiomyopathy. LVEF assessment required. |
| Venetoclax | No dose adjustment for renal impairment per label. | Severe hepatic impairment (Child-Pugh C): reduce to 100 mg QD. | CYP3A4 DDI adjustments mandatory (see Section 6). |
| Azacitidine | SCr rises during treatment: if SCr doubles → hold dose until SCr returns to normal. | Serum bicarb <20 mEq/L: reduce next cycle dose by 50%. | |
| Decitabine | No formal recommendations; monitor closely. | No formal recommendations; monitor LFTs. | |
| Midostaurin | No adjustment needed. | No adjustment for mild-moderate impairment. | CYP3A4 substrate: reduce with strong inhibitors; avoid inducers. |
| Gilteritinib | No dose adjustment needed (not renally excreted). | No dose adjustment for mild-moderate impairment. | CYP3A4 substrate. Avoid strong CYP3A4 inducers. |
| Quizartinib | No dose adjustment for renal impairment. | Moderate hepatic impairment: no adjustment required per label. | QTcF >500 ms → hold. Strong CYP3A4 inhibitors → reduce dose to 17.7 mg. |
| Ivosidenib | No dose adjustment needed. | No dose adjustment for mild-moderate. | QTc monitoring. Take consistently with or without food. Strong CYP3A4 inhibitors increase levels. |
| Enasidenib | No dose adjustment needed. | No dose adjustment. | Watch for differentiation syndrome. Bilirubin elevation can occur (IDH2 inhibition → unconjugated bilirubin ↑, not hepatotoxicity). |
| Olutasidenib | No formal adjustment. | Avoid in severe hepatic impairment. | QTc monitoring. CYP3A4 substrate. |
| GO (Gemtuzumab) | No dose adjustment. | Avoid in severe hepatic impairment or VOD/SOS. | VOD risk increases with prior or planned alloHCT. Do not administer if active hepatic VOD. |
| CPX-351 | No dose adjustment. | Bilirubin 1.5–3 mg/dL: not adequately studied. Bili >3 mg/dL: avoid. | Monitor LVEF (daunorubicin component). Count recovery longer than standard 7+3. |
| Rasburicase | No dose adjustment. | No dose adjustment. | CONTRAINDICATED: G6PD deficiency, pregnancy, lactation. Single dose usually sufficient; repeat if needed. |
| Revumenib | No dose adjustment. | Severe impairment: not established. | Dose depends on CYP3A4 inhibitor co-administration. <40 kg: weight-based dosing per prescribing info. |
⚠️ PHARMACIST WATCHOUT: ENASIDENIB: Elevated unconjugated bilirubin is a class effect of IDH2 inhibition (reduced UGT1A1 activity) – NOT true liver toxicity. Do NOT erroneously reduce/hold the drug based on isolated bilirubin elevation without other LFT abnormalities. Educate the team and document.
SECTION 12: KEY DRUG REFERENCE TABLE
| Drug (Brand) | Class/MOA | Key Clinical Pearls / Counseling / Pharmacist Watchouts |
| Venetoclax (Venclexta) | BCL-2 inhibitor. Inhibits anti-apoptotic BCL-2 protein → restores apoptosis in leukemic cells. | Ramp-up dosing with HMA (100→200→400 mg) or LDAC (100→200→400→600 mg). DDI: Major CYP3A4 substrate: reduce dose with azole antifungals (posaconazole/voriconazole → strong; fluconazole → moderate). Avoid grapefruit, Seville oranges (CYP3A4 inhibition). Avoid strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin). TLS risk in C1: inpatient monitoring required. Check electrolytes Q6–8h during ramp-up. Take with food (increases absorption ~5-fold). |
| Midostaurin (Rydapt) | Multi-kinase inhibitor (FLT3-ITD/TKD, KIT, PDGFR). Inhibits FLT3 signaling → apoptosis. | Give on Days 8–21 of 7+3 (NOT with cytarabine/anthracycline, to avoid overlapping hematotoxicity). Continue as maintenance up to 12 cycles post-consolidation. N-desmethyl metabolite is active. DDI: CYP3A4 substrate: with azoles (alternative antifungal: micafungin – not a CYP3A4 inhibitor). Take with food (reduces GI toxicity). N/V is common (premed). |
| Quizartinib (Vanflyta) | Selective FLT3-ITD inhibitor (type II). ITD only, NOT TKD. | QuANTUM-First trial (OS benefit in FLT3-ITD+). Not active against TKD mutations (use gilteritinib or midostaurin instead). QTcF monitoring mandatory: baseline ECG, replete electrolyte prior QC. Dose is QTcF-guided: 26.5 mg C1D1–14; 53 mg if QTcF ≤450 ms. DDI: CYP3A4 substrate: strong inhibitors [ZA21] → reduce to 17.7 mg. |
| Gilteritinib (Xospata) | Selective FLT3 and AXL inhibitor (type I). Active against FLT3-ITD AND TKD mutations. | ADMIRAL trial: OS benefit in R/R FLT3+ AML vs. salvage chemo. Post-HCT maintenance for MRD+ FLT3-ITD (new NCCN update). Differentiation syndrome risk (fever, SOB/hypoxia, edema). Treat with dexamethasone 10 mg IV Q12h. QTc monitoring. CYP3A4 substrate (Avoid with strong CYP3A4 inducers). |
| ATRA – Tretinoin (Vesanoid) | Differentiating agent. Binds PML::RARA fusion protein → releases co-repressor complex → differentiates malignant promyelocytes. | START at first clinical suspicion of APL – do NOT wait for cytogenetics! Differentiation syndrome: ppx prednisone from D1. Switch to dexamethasone if differentiation syndrome develops. QTc monitoring (mild risk). Hepatotoxicity (monitor LFTs). Pseudotumor cerebri: headache, vision changes → reduce dose. Teratogenic: strict contraception required. Vitamin A toxicity (dry skin, cheilitis, elevated triglycerides). |
| Arsenic Trioxide (Trisenox) | Promotes PML::RARA degradation, induces apoptosis and differentiation of APL cells. | QTcF monitoring DAILY: QTcF >500 ms → HOLD. Replete K+, Mg²+, Ca²+ aggressively. Differentiation syndrome risk (same as ATRA). Peripheral neuropathy with prolonged use. Avoid concomitant QT-prolonging medications. Dilute in D5W or NS. Stable 24h at room temperature. |
| Gemtuzumab Ozogamicin (Mylotarg) | Anti-CD33 ADC (antibody-drug conjugate). Binds CD33 on leukemic cells → delivers calicheamicin → DNA damage. | Verify CD33 expression first! VOD/SOS risk: monitor LFTs, weight, RUQ pain. Risk increases with prior/subsequent alloHCT. Do not use in patients with hepatic VOD/SOS. Defibrotide available for VOD treatment. Infuse over 2 hours. Premedicate (acetaminophen + diphenhydramine). Thrombocytopenia – common and prolonged. |
| Ivosidenib (Tibsovo) | IDH1 inhibitor. Reduces 2-hydroxyglutarate (2-HG) production → restores normal differentiation. | AgIQ trial data (+ aza) for frontline use. IDH1 mutation required. Differentiation syndrome risk (similar to ATRA). Monitor and treat with dexamethasone. QTc prolongation: baseline ECG, electrolyte management. Food effect variable – take consistently. CYP3A4 substrate: dose adjust with strong inhibitors. |
| Enasidenib (Idhifa) | IDH2 inhibitor. Reduces 2-HG → restores myeloid differentiation. | IDH2 mutation required. Differentiation syndrome: more common in IDH2-R140 vs R172. Fever, dyspnea → dexamethasone. BILIRUBIN ELEVATION: Unconjugated hyperbilirubinemia is a class effect (NOT hepatotoxicity). Do NOT hold/stop for isolated elevated indirect bilirubin without other LFT derangement. Nausea/vomiting, diarrhea common. |
| Olutasidenib (Rezlidhia) | IDH1 inhibitor (oral, twice daily). Active against IDH1-R132 mutations. | IDH1-specific. Take with or without food. QTc monitoring. Differentiation syndrome risk. CYP3A4 substrate. Approved based on AUGMENT-101 trial. |
| Revumenib (Revuforj) | Menin inhibitor. Blocks menin-KMT2A interaction → disrupts oncogenic transcription in KMT2A-rearranged or NPM1-mutant AML. | DOSE IS CYP3A4 INHIBITOR DEPENDENT: 160 mg BID (with strong CYP3A4 inhibitor) vs. 270 mg BID (without). Verify concomitant antifungals! Differentiation syndrome risk. QTc prolongation monitoring. Weight-based dosing for <40 kg patients. NPM1 mutation OR KMT2A rearrangement required. FDA approved 2023. |
| Ziftomenib (Zilbrysq) | Menin inhibitor (oral, once daily). NPM1-mutant R/R AML. | NPM1 mutation required. FDA approved 2025 – newer agent, monitor for emerging safety data. Differentiation syndrome risk. DDI profile: CYP3A4 substrate – review concomitant medications. |
| Oral Azacitidine (Onureg / CC-486) | Oral hypomethylating agent. DNA methyltransferase inhibitor → re-expression of silenced tumor suppressor genes. | NOT bioequivalent to injectable azacitidine 75 mg/m²! Do NOT substitute. Approved for maintenance (300 mg PO Days 1–14 per 28-day cycle) in AML in CR/CRi post-intensive therapy. QUAZAR AML-001: OS benefit 24.7 vs. 14.8 months. Nausea: most common side effect. Take on empty stomach to minimize. No food restriction technically, but consistency matters. |
| Cytarabine (Cytosar-U) | Antimetabolite (pyrimidine analog). Incorporated into DNA → chain termination; inhibits DNA polymerase. | HiDAC (≥1 g/m²): steroid eye drops mandatory. Neuro exam before each HiDAC dose. CEREBELLAR TOXICITY: STOP immediately, no rechallenge. Flu-like syndrome: fever, myalgia (hours after standard-dose). Nausea/vomiting: antiemetics. Renal dose adjustment for CrCl <60 (if ≥2 g/m²). Age ≥60 y: max 1–1.5 g/m² for HiDAC. |
| CPX-351 (Vyxeos) | Liposomal formulation of cytarabine:daunorubicin (5:1 molar ratio). Liposomes preferentially taken up by leukemic cells. | Do NOT substitute with individual cytarabine + daunorubicin. Infuse over 90 minutes. Count recovery delayed vs. standard 7+3 – educate team. Cardiotoxicity monitoring (daunorubicin component). FDA approved for secondary AML, therapy-related AML, AML-MRC. Category 1 for age ≥60 y with secondary AML features (ADMIRAL trial framework). |
SECTION 13: AML RESPONSE CRITERIA (AML-I)
Source: NCCN AML v3.2026 AML-I | Standard ELN 2022 Response Definitions
| Response | Definition | Clinical Significance |
| CR (Complete Remission) | BM blasts <5%, no Auer rods, no extramedullary disease. ANC ≥1 x 10⁹/L. Platelets ≥100 x 10⁹/L. Transfusion independent. | Goal of induction therapy. |
| CRi (CR with incomplete count recovery) | CR criteria except ANC <1 x 10⁹/L and/or platelets <100 x 10⁹/L | Common after venetoclax-based regimens. Still meaningful response. |
| CRh (CR with partial hematologic recovery) | CR criteria except ANC ≥0.5 but <1 x 10⁹/L and/or platelets ≥50 but <100 x 10⁹/L | Partial count recovery. |
| MLFS (Morphologic Leukemia-Free State) | BM blasts <5%, no complete count recovery | Meaningful response in venetoclax context; proceed with therapy. |
| MRD-negative CR (CR MRD-) | CR + no detectable MRD by flow, PCR, or NGS | Best prognostic outcome; may allow de-escalation of post-remission therapy in favorable risk. |
| Primary Refractory | Inability to attain CR, CRh, or CRi following ≥2 courses of intensive induction therapy | Poor prognosis; consider salvage and alloHCT evaluation. |
| Relapse | Reappearance of leukemic blasts in peripheral blood OR ≥5% blasts in BM (not attributable to recovery) | Distinguish from BM regeneration post-consolidation. |
| MRD Relapse (NEW v3.2026) | Conversion from MRD negativity to MRD positivity (any method) | New category added per latest update. Treatment implications evolving. |
💎 CLINICAL PEARL: CLINICAL PEARL: In venetoclax-based regimens, CRi (without complete platelet/ANC recovery) is a valid and expected response. Prolonged cytopenias do NOT always indicate treatment failure. BM biopsy at days 21–28 is the guide – if <5% blasts, proceed with dose modification per AML-J algorithm.
SECTION 14: MASTER CLINICAL PEARLS & PHARMACIST WATCHOUTS
Comprehensive summary for rounds, tumor board, chemo review, and patient counseling
🔑 Top 20 Clinical Pearls for AML Pharmacotherapy
💎 1. ATRA in APL: Start IMMEDIATELY at first clinical suspicion (life-saving, avoid fatal DIC). DONT wait for cytogenetics.
💎 2. G6PD check prior rasburicase (risk for severe hemolytic anemia). If urgent/G6PD status unknown, consider allopurinol.
💎 3. CPX-351 ≠ 7+3: The liposomal formulation has different PK/toxicity. Do NOT substitute components. Count recovery takes longer. Category 1 for secondary/therapy-related AML in age ≥60 y.
💎 4. Venetoclax DDI is CRITICAL: Posaconazole (strong CYP3A4 inhibitor) increases venetoclax exposure significantly. Dose must be reduced (per package insert). Document adjustment in chart.
💎 5. Quizartinib: QTcF >500 ms → HOLD. ITD-specific (does NOT cover TKD). Different from midostaurin/gilteritinib which cover both ITD and TKD.
💎 6. HiDAC Eye Drops: Prednisolone 1% BID to each eye from Day 1 through 24–72h post-cytarabine. If not ordered → chemical keratoconjunctivitis. This is a MUST-order item.
💎 7. HiDAC Neurotoxicity: Age ≥60 y and CrCl <60 mL/min → highest risk. Neuro exam before EACH dose. Ataxia/nystagmus/dysarthria = STOP permanently, no rechallenge with ≥2 g/m².
💎 8. Enasidenib Bilirubin: Elevated unconjugated bilirubin is expected (class effect of IDH2 inhibition, not hepatotoxicity). Educate team. Do NOT hold drug for isolated bilirubin rise without other LFT abnormalities.
💎 9. Revumenib dose depends on antifungal: 160 mg BID WITH strong CYP3A4 inhibitor (posaconazole/voriconazole). 270 mg BID WITHOUT. This is a critical prescribing and verification point.
💎 10. Oral azacitidine (Onureg) 300 mg ≠ injectable azacitidine 75 mg/m². Different bioavailability, different indication (maintenance). Do NOT interchange.
💎 11. TLS in venetoclax/AML: Inpatient monitoring during cycle 1 ramp-up is strongly recommended. WBC must be <25 x 10⁹/L before starting. Electrolytes Q6–8h during ramp-up.
💎 12. FLT3-ITD MRD ≥10⁻⁶ by NGS pre/post-alloHCT: Post-transplant gilteritinib maintenance is now recommended per NCCN v3.2026. This is a new indication.
💎 13. Etoposide: Use non-PVC tubing (DEHP leaching from PVC). Monitor for hypersensitivity. Secondary AML/MDS risk with cumulative use.
💎 14. G-CSF: STOP ≥7d before bone marrow biopsy to avoid misinterpreting neutrophil recovery as persistent leukemia.
💎 15. APL Differentiation Syndrome: Dexamethasone 10 mg IV Q12h at first sign. Generally do NOT stop ATRA/ATO for mild-moderate syndrome. Do NOT confuse with infection.
💎 16. IDH inhibitor differentiation syndrome (ivosidenib, enasidenib, olutasidenib, revumenib): same principle – dexamethasone, generally continue drug unless severe.
💎 17. Midostaurin + azole antifungals: Significant CYP3A4 DDI. Institutional practice often switches to micafungin (not a CYP3A4 inhibitor) during midostaurin therapy.
💎 18. TP53-mutant AML: Lowest venetoclax benefit. NCCN preferred recommendation = CLINICAL TRIAL. Do not assume venetoclax will be effective.
💎 19. ATO QTcF monitoring: Obtain ECG and electrolytes (K+, Mg²+, Ca²+) DAILY during ATO therapy. QTcF >500 ms → HOLD until corrected.
💎 20. Response criteria update: MRD relapse is now a distinct category per NCCN v3.2026 (conversion from MRD-neg to MRD-pos). FLT3-ITD MRD guidance now explicitly guides post-HCT maintenance decision.
⚠️ Top 10 Pharmacist Watchouts During Multidisciplinary Rounds
⚠️ 1. VERIFY FLT3 mutation type before FLT3 inhibitor selection: Quizartinib = ITD ONLY. Midostaurin/Gilteritinib = ITD AND TKD. Wrong drug selection is a clinically significant error.
⚠️ 2. VENETOCLAX DOSE ADJUSTMENT WITH ANTIFUNGALS: At every cycle review, check concurrent antifungals and confirm venetoclax dose has been adjusted. This is the #1 pharmacist DDI catch in AML.
⚠️ 3. CONFIRM CD33 EXPRESSION before gemtuzumab ozogamicin – both for induction and single-agent use. Check the flow cytometry or IHC report.
⚠️ 4. MONITOR CUMULATIVE ANTHRACYCLINE DOSE: Track daunorubicin (from 7+3 and CPX-351), idarubicin, mitoXANTRONE (anthracycline equivalent). Use conversion factors. Lifetime limit considerations before each course.
⚠️ 5. CEREAL NEUROTOX NEURO EXAM DOCUMENTATION: Verify that the bedside neuro exam was done before every HiDAC dose and is DOCUMENTED. Flag if not done.
⚠️ 6. CHECK QTcF AT EVERY CYCLE: For quizartinib, ivosidenib, olutasidenib, ATO, sorafenib, revumenib. Review ECG, current K+/Mg²+ levels, and concomitant QT-prolonging medications.
⚠️ 7. ANTIMICROBIAL PROPHYLAXIS DDI REVIEW: Posaconazole (preferred antifungal in AML per NCCN) is a strong CYP3A4 inhibitor. Always review it against all concurrent targeted therapies.
⚠️ 8. RASBURICASE + ALLOPURINOL = CONTRAINDICATED COMBINATION. Cannot use both simultaneously. Rasburicase converts uric acid to allantoin; allopurinol blocks xanthine oxidase. If rasburicase given, stop allopurinol.
⚠️ 9. STEROID EYE DROPS ORDER VERIFICATION: For every HiDAC course, verify prednisolone 1% eye drops are ordered bilaterally, starting Day 1, continuing 24–72h post-cytarabine. Common omission error.
⚠️ 10. ENASIDENIB BILIRUBIN ALERT: If team plans to hold/reduce enasidenib for isolated bilirubin elevation → intervene. Unconjugated hyperbilirubinemia is a class effect of IDH2 inhibition. Distinguish from true hepatotoxicity (transaminase elevation pattern).
SECTION 15: QUICK REFERENCE CARDS
15.1 Transfusion Thresholds
| Blood Product | Threshold (NCCN AML-F) | Special Circumstances |
| RBCs | Hgb ≤7–8 g/dL (or symptomatic anemia) | Leukocyte-depleted; CMV-neg for HCT candidates; irradiated for alloimmunized or pre-HCT. |
| Platelets | Plt <10,000/mcL OR any active bleeding | Alloimmunized: HLA-matched/crossmatch-compatible products. In APL: maintain >50,000/mcL due to DIC risk. |
| FFP/Cryoprecipitate | APL/DIC: Fibrinogen <150 mg/dL → cryoprecipitate; PT prolonged → FFP | DIC in APL is a hematologic emergency. Replace aggressively. |
15.2 TLS Monitoring Protocol Summary
| Timepoint | Action |
| Before venetoclax initiation | WBC <25 x 10⁹/L (hydroxyurea/leukapheresis). Allopurinol or rasburicase. G6PD check. IV hydration. |
| During ramp-up (Cycle 1 D1–4) | Inpatient. Labs (electrolytes, uric acid, Cr, phos, LDH) Q6–8h after initiation x24h after maximum dose. |
| After maximum dose achieved | Daily chemistry monitoring until TLS risk resolved. |
| Electrolyte management | K+, Phos, Ca²+, uric acid. Sodium polystyrene for hyperkalemia (use cautiously); sevelamer/calcium carbonate for hyperphosphatemia; calcium for hypocalcemia; rasburicase/allopurinol for hyperuricemia. |
15.3 Differentiation Syndrome – Rapid Response Card
| Feature | Detail |
| Trigger | ATRA, ATO, IDH inhibitors (ivosidenib, enasidenib, olutasidenib), FLT3 inhibitors (gilteritinib), Menin inhibitors (revumenib, ziftomenib) |
| Signs/Symptoms | Fever ≥38°C, dyspnea, pulmonary infiltrates, pleural/pericardial effusion, hypoxia, weight gain ≥5 kg, hypotension, renal failure, edema |
| Treatment | Dexamethasone 10 mg IV Q12h until resolution (typically ≥3 days) |
| Drug management | Do NOT stop the causative agent unless Grade 3–4 refractory to dexamethasone |
| Differentiate from infection | Blood cultures, CXR, clinical judgment – both can coexist |
| Special APL note | Prednisone prophylaxis from ATRA Day 1 (switch to dexamethasone if DS develops) |
15.4 QTc Management Quick Card
| Drug | QTcF Threshold | Action if Exceeded |
| Quizartinib | >500 ms (or >450 ms to escalate from 26.5 to 53 mg) | Hold. Replete K+/Mg²+. Recheck ECG. If resolves to ≤480 ms, restart at lower dose. Maintain 26.5 mg if QTcF >500 ms at any time. |
| ATO (Arsenic Trioxide) | >500 ms | HOLD. Aggressively replete electrolytes. Recheck in 24h. Restart only when <450 ms. |
| Ivosidenib | >500 ms | Hold. Replete electrolytes. Restart at reduced dose if indicated. |
| Olutasidenib | >500 ms | Hold/dose-reduce per prescribing information. |
| Revumenib | ≥500 ms or increase >60 ms from baseline | Hold. Electrolyte repletion. Restart at reduced dose per prescribing info. |
| Sorafenib | >500 ms | Hold. Manage electrolytes. Reassess benefit/risk. |
REFERENCE: NCCN Clinical Practice Guidelines in Oncology – Acute Myeloid Leukemia, Version 3.2026, November 24, 2025. NCCN Chemotherapy Order Template AML34 (MEC), v1.2026. ELN 2022 Risk Stratification (Döhner H, et al. Blood 2022;140:1345-1377). Compiled for educational use by a Hematology/Oncology Pharmacotherapy Specialist.